Last reviewed · How we verify
TNK-tPA
TNK-tPA is a genetically engineered tissue plasminogen activator that converts plasminogen to plasmin to dissolve blood clots.
TNK-tPA is a genetically engineered tissue plasminogen activator that converts plasminogen to plasmin to dissolve blood clots. Used for Acute myocardial infarction (AMI), Acute ischemic stroke.
At a glance
| Generic name | TNK-tPA |
|---|---|
| Also known as | rtPA |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
TNK-tPA (tenecteplase) is a fibrinolytic agent derived from natural tissue plasminogen activator (tPA) with amino acid substitutions that improve its pharmacokinetic properties. It binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix and dissolves the clot. The modifications make it more fibrin-specific and resistant to plasminogen activator inhibitor-1 compared to wild-type tPA, allowing for faster administration and improved efficacy.
Approved indications
- Acute myocardial infarction (AMI)
- Acute ischemic stroke
Common side effects
- Bleeding (major and minor)
- Intracranial hemorrhage
- Hypotension
- Arrhythmias
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNK-tPA CI brief — competitive landscape report
- TNK-tPA updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI